Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 28 Oct 2023
ImmunoGen announces European Medicines Agency acceptance of marketing authorisation application for mirvetuximab soravtansine in platinum-resistant ovarian cancer
27 October 2023 - ImmunoGen today announced that the EMA has accepted the marketing authorisation application for mirvetuximab soravtansine (Elahere) ...
Posted by Michael Wonder on 27 Oct 2023
PHARMAC boss apologises over stories of patients self-funding treatments
28 October 2023 - PHARMAC's chief executive has apologised for making unprofessional comments about a journalist and stories of cancer ...
Posted by Michael Wonder on 27 Oct 2023
How health care costs stopped rising
26 October 2023 - For a long time, health care was eating the world. From 1950 to 2009 American spending on ...
Posted by Michael Wonder on 27 Oct 2023
Terminal cancer patient wants 'complete overhaul' of PHARMAC
27 October 2023 - Instead of spending time with her six-year-old daughter, terminal cancer patient Vickie Hudson-Craig is fighting PHARMAC ...
Posted by Michael Wonder on 27 Oct 2023
Drugs are outrageously expensive—Canada found a way to fight back
27 October 2023 - Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the US. ...
Posted by Michael Wonder on 27 Oct 2023
FDA approves Genentech’s Vabysmo for the treatment of retinal vein occlusion
27 October 2023 - Approval is based on two Phase 3 studies demonstrating early and sustained vision improvements that were non-inferior ...
Posted by Michael Wonder on 27 Oct 2023
Organon Canada announces availability of a high concentration, citrate free formulation of Hadlima, a biosimilar to Humira
26 October 2023 - Hadlima 40 mg/0.4 mL offers a higher concentration compared to Hadlima 40 mg/0.8 mL. ...
Posted by Michael Wonder on 27 Oct 2023
PHARMAC Board endorse action plan to enhance organisational culture
27 October 2023 - At PHARMAC’s regular monthly Board meeting held today, the Board endorsed the action plan proposed by the ...
Posted by Michael Wonder on 27 Oct 2023
Public Summary Documents – July 2023 PBAC meeting
27 October 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2023 PBAC ...
Posted by Michael Wonder on 27 Oct 2023
Legislation expands access to breakthrough Alzheimer’s treatment
26 October 2023 - There’s new hope in the fight against Alzheimer’s. Federal legislation called the Access to Innovative Treatments ...
Posted by Michael Wonder on 27 Oct 2023
Catalyst Pharmaceuticals reports FDA approval of Agamree (vamorolone) for Duchenne muscular dystrophy granted to Santhera Pharmaceuticals
26 October 2023 - Catalyst expects to commercially launch Agamree in Q1, 2024. ...
Posted by Michael Wonder on 27 Oct 2023
Health Canada authorises CSL's Hemgenix (etranacogene dezaparvovec) as first gene therapy for haemophilia B
26 October 2023 - CSL's Hemgenix is a one time, single dose treatment for adults with haemophilia B who require ...
Posted by Michael Wonder on 27 Oct 2023
Altimmune granted fast track designation by FDA for pemvidutide for the treatment of non-alcoholic steatohepatitis
26 October 2023 - Altimmune today announced that the US FDA has granted fast track designation to its clinical program ...
Posted by Michael Wonder on 26 Oct 2023
Oncternal Therapeutics announces FDA granted fast track designation for ONCT-534 for the treatment of metastatic castration-resistant prostate cancer
26 October 2023 - Oncternal Therapeutics today announced that the US FDA has designated ONCT-534, its novel dual-acting androgen receptor inhibitor, ...
Posted by Michael Wonder on 26 Oct 2023
FDA approves Lilly's Omvoh (mirikizumab-mrkz), a first in class treatment for adults with moderately to severely active ulcerative colitis
26 October 2023 - Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials. ...